## Gene Summary
HCN1, or Hyperpolarization-activated cyclic nucleotide-gated potassium channel 1, is a protein-coding gene involved in the electrical activity of the heart and central nervous system. HCN1 encodes a member of the hyperpolarization-activated cyclic nucleotide-gated (HCN) channel family, which functions in generating rhythmic activity both in the heart and the brain. These channels are characterized by their activation through hyperpolarization and their permeability to both potassium and sodium ions. HCN1 is predominantly expressed in the cerebral cortex and hippocampus, areas of the brain associated with higher cognitive function and memory processing.

## Gene Drugs, Diseases, Phenotypes, and Pathways
HCN1 is linked notably to the control of neuronal excitability and has implications in several neurological disorders. Diseases such as epilepsy, particularly temporal lobe epilepsy, and neuropathic pain might be associated with dysfunction of this gene. The HCN channels, in general, participate in setting the resting membrane potential and control the responsiveness of the neurons to synaptic inputs. This role situates HCN1 within significant neurophysiological pathways, including those involved in circadian rhythms and neuronal pacemaker activity. Current studies largely focus on how modulation of these channels can impact diseases such as depression, schizophrenia, and epilepsy.

## Pharmacogenetics
The pharmacogenetics of HCN1 is relatively nascent but growing due to its importance in modulating brain activity. Ivabradine, a heart rate-reducing medication, acts by inhibiting HCN channels, though its specificity to HCN1 in the brain versus cardiac-specific HCN4 needs clearer delineation. Research into drugs targeting HCN1 specifically in the context of central nervous system disorders is ongoing, with interest in mechanisms by which modulation of HCN1 might affect conditions like epilepsy and pain disorders. While there is not a broad range of medications presently known to interact specifically with HCN1, ongoing advancements in neuromodulatory treatments may potentially recognize new therapeutic targets within HCN1-associated pathways.